Stryker Co. (NYSE:SYK) Shares Sold by Fiduciary Family Office LLC

05 Nov 2024, 12:42 by Scott Moore · The Cerbat Gem

Fiduciary Family Office LLC decreased its position in shares of Stryker Co. (NYSE:SYK – Free Report) by 46.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,929 shares of the medical technology company’s stock after selling 1,685 shares during the quarter. Fiduciary Family Office LLC’s holdings in Stryker were worth $697,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of SYK. Koshinski Asset Management Inc. acquired a new stake in shares of Stryker during the first quarter worth $795,000. Envestnet Portfolio Solutions Inc. boosted its holdings in shares of Stryker by 43.1% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 18,491 shares of the medical technology company’s stock valued at $6,617,000 after buying an additional 5,565 shares during the period. BI Asset Management Fondsmaeglerselskab A S raised its position in shares of Stryker by 38.5% during the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 19,796 shares of the medical technology company’s stock worth $7,084,000 after buying an additional 5,502 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in Stryker by 78.9% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 133,020 shares of the medical technology company’s stock valued at $45,260,000 after purchasing an additional 58,673 shares during the last quarter. Finally, M&G Plc acquired a new stake in shares of Stryker during the first quarter valued at approximately $11,534,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on SYK. Robert W. Baird upped their price objective on shares of Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. BTIG Research raised their target price on shares of Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Truist Financial lifted their price objective on shares of Stryker from $370.00 to $380.00 and gave the stock a “hold” rating in a research report on Wednesday, October 30th. Piper Sandler reissued an “overweight” rating and set a $420.00 target price (up previously from $380.00) on shares of Stryker in a research note on Wednesday, October 30th. Finally, Wells Fargo & Company increased their price target on Stryker from $381.00 to $405.00 and gave the stock an “overweight” rating in a report on Wednesday, October 30th. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $393.65.

Get Our Latest Stock Analysis on SYK

Stryker Trading Up 0.2 %

Shares of NYSE SYK traded up $0.67 during mid-day trading on Tuesday, reaching $367.57. The company had a trading volume of 327,124 shares, compared to its average volume of 1,252,005. The stock has a market cap of $140.12 billion, a price-to-earnings ratio of 39.32, a price-to-earnings-growth ratio of 2.77 and a beta of 0.91. The business’s 50-day moving average is $360.43 and its 200-day moving average is $344.64. Stryker Co. has a 52 week low of $266.93 and a 52 week high of $374.63. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK – Get Free Report) last posted its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, topping the consensus estimate of $2.77 by $0.10. The firm had revenue of $5.49 billion during the quarter, compared to analyst estimates of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. Stryker’s revenue was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.46 EPS. Equities analysts expect that Stryker Co. will post 12.06 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, October 31st. Shareholders of record on Monday, September 30th were given a dividend of $0.80 per share. The ex-dividend date of this dividend was Monday, September 30th. This represents a $3.20 dividend on an annualized basis and a yield of 0.87%. Stryker’s dividend payout ratio is currently 34.30%.

Insiders Place Their Bets

In other Stryker news, VP M Kathryn Fink sold 7,347 shares of the stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $366.98, for a total value of $2,696,202.06. Following the sale, the vice president now directly owns 10,042 shares of the company’s stock, valued at approximately $3,685,213.16. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. In other Stryker news, VP M Kathryn Fink sold 7,347 shares of the business’s stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $366.98, for a total value of $2,696,202.06. Following the transaction, the vice president now directly owns 10,042 shares of the company’s stock, valued at approximately $3,685,213.16. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Viju Menon sold 600 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total transaction of $213,000.00. Following the completion of the sale, the insider now owns 9,069 shares of the company’s stock, valued at approximately $3,219,495. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 10,068 shares of company stock worth $3,693,972. Corporate insiders own 5.90% of the company’s stock.

About Stryker

(Free Report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.